{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:52Z","timestamp":1790217412344,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.oret.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T04:27:28Z","timestamp":1645504048000},"page":"628-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-7682","authenticated-orcid":false,"given":"Brian W.","family":"Fleck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Marlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Weisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair R.","family":"Fielder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2022.02.006_bib1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2022.02.006_bib2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A\u00a0dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.02.006_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.02.006_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.oret.2022.02.006_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.02.006_bib6","first-page":"323","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2022.02.006_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2022.02.006_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open-label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.oret.2022.02.006_bib9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.02.006_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.0006-341X.2005.030815.x","article-title":"Quantile regression models with multivariate failure time data","volume":"61","author":"Yin","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.oret.2022.02.006_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/aos.14532","article-title":"Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data","volume":"99","author":"Pivodic","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.oret.2022.02.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity. 3rd ed","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.02.006_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A\u00a0spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.02.006_bib14","first-page":"350","article-title":"Retinal vessel changes after laser treatment for retinopathy of prematurity","volume":"16","author":"Kwon","year":"2012","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2022.02.006_bib15","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1021\/mp500160v","article-title":"Comparison of binding characteristics and in\u00a0vitro activities of three inhibitors of vascular endothelial growth factor A","volume":"11","author":"Yang","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.oret.2022.02.006_bib16","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell\u2013derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.02.006_bib17","first-page":"105","article-title":"Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity","volume":"1","author":"Young","year":"1997","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2022.02.006_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/aos.14406","article-title":"Inadequate laser coagulation is an important cause of treatment failure in type 1 retinopathy of prematurity","volume":"98","author":"Spandau","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2022.02.006_bib19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.02.006_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.02.006_bib21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.02.006_bib22","first-page":"5078565","article-title":"Recurrence of retinopathy of prematurity in Zone II Stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.oret.2022.02.006_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the rainbow trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:30:16Z","timestamp":1762853416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653022000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2468653022000653"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2022.02.006","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}